
Opinion|Videos|December 19, 2024
Evolving First-Line Treatment Strategies for uHCC.
Author(s)James J. Harding, MD
James J. Harding, MD, provides a high-level overview of systemic therapy for untreated unresectable hepatocellular carcinoma (uHCC) based on NCCN Guidelines, and discusses the evolving treatment landscape, including the rationale for combination immunotherapy (IO) and how additional IO combinations may address unmet needs like depth of response and resistance.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
Give a high-level overview of systemic therapy for untreated uHCC
Briefly dDiscuss the evolving treatment landscape of systemic therapy in untreated uHCC.
- What has been the rationale for combination immunotherapy (IO) in this setting?
- What are current unmet needs, and how could additional IO combinations address them?
- E.g,. depth of response, resistance,…
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















